The protective mechanism of Dehydromiltirone in diabetic kidney disease is revealed through network pharmacology and experimental validation

The protective mechanism of Dehydromiltirone in diabetic kidney disease is revealed through network pharmacology and experimental validation

Background:Salvia miltiorrhiza (SM) is an effective traditional Chinese medicine for treating DKD, but the exact mechanism is elusive. In this study, we aimed to investigate and confirm the method underlying the action of the active components of SM in the treatment of DKD.Methods: Renal tissue tran...

Full description

Bibliographic Details
Main Authors:	Yanzhe Wang, Yuyuan Liu, Sijia Chen, Fengqin Li, Yue Wu, Xinmiao Xie, Nan Zhang, Chuchu Zeng, Linnan Bai, Mengshi Dai, Ling Zhang, Xiaoxia Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Pharmacology
Subjects:	diabetic kidney disease network pharmacology molecular docking Dehydromiltirone PIK3CA
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1201296/full

Similar Items

Investigating the effect of dehydromiltirone on septic AKI using a network pharmacology method, molecular docking, and experimental validation
by: Sijia Chen, et al.
Published: (2023-03-01)

Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity
by: Wei Deng, et al.
Published: (2022-09-01)

Network pharmacology and molecular docking of endogenous active metabolites in diabetic kidney disease
by: Xinmiao Xie, et al.
Published: (2023-12-01)

Network pharmacology, molecular docking and experimental verification help unravel chelerythrine's potential mechanism in the treatment of gastric cancer
by: Kang Kai, et al.
Published: (2023-07-01)

Profiling PIK3CA variants in disorders of somatic mosaicism
by: Bahareh A. Mojarad, et al.
Published: (2023-01-01)

Identification of PIK3CG as a hub in septic myocardial injury using network pharmacology and weighted gene co‐expression network analysis
by: Qiong Liu, et al.
Published: (2023-01-01)

Editorial: Bone and Cartilage Diseases – The Role and Potential of Natural Products, Volume II
by: Ming Pei, et al.
Published: (2023-05-01)

Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature and peripheral venous dilatation: parks weber syndrome or PROS?
by: Li Xin Su, et al.
Published: (2022-01-01)

Views on the Current Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum
by: SUN Liying, et al.
Published: (2023-10-01)

PIK3CA-related overgrowth spectrum: animal model and drug discovery
by: Venot, Quitterie, et al.
Published: (2021-07-01)

Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer
by: Snježana Ramić, et al.
Published: (2023-01-01)

Integrative applications of network pharmacology and molecular docking: An herbal formula ameliorates H9c2 cells injury through pyroptosis
by: Zhongwen Qi, et al.
Published: (2023-03-01)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
by: Katherine E. Hutchinson, et al.
Published: (2023-04-01)

Colorectal cancer chemoprevention: is aspirin still in the game?
by: Adrien Grancher, et al.
Published: (2022-12-01)

NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models
by: Hua Li, et al.
Published: (2022-01-01)

The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
by: Li Shuo, et al.
Published: (2023-11-01)

Amelioration of Cisplatin-Induced kidney injury by Arabinogalactan based on network pharmacology and molecular docking
by: Jian-Qiang Wang, et al.
Published: (2023-05-01)

Somatic mutation spectrum of a Chinese cohort of pediatrics with vascular malformations
by: Bin Zhang, et al.
Published: (2023-09-01)

Anwuligan inhibits the progression of non‐small cell lung cancer via let‐7c‐3p/PI3K/AKT/mTOR axis
by: Huikun Niu, et al.
Published: (2023-03-01)

Dissection of <i>PIK3CA</i> Aberration for Cervical Adenocarcinoma Outcomes
by: Tony K. H. Chung, et al.
Published: (2021-06-01)

Gene polymorphisms in ULK1 and PIK3CA are associated with the risk of microscopic polyangiitis in the Guangxi Zhuang Autonomous Region in China
by: Yan Zhu, et al.
Published: (2021-11-01)

CLOVES syndrome caused by mosaic mutation in the PIK3CA gene identified in fibroblasts
by: Magdalena Kłaniewska, et al.
Published: (2021-07-01)

Recurrent <i>PIK3CA H1047R</i>-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature
by: Kei Shing Oh, et al.
Published: (2023-02-01)

A Neonate Diagnosed with Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome with Mutation
by: Young Mi Park, et al.
Published: (2023-05-01)

Polymorphic GT Dinucleotide Repeat in the PIK3CA Gene and its Association with Colorectal Cancer Risk
by: Soha Parsafar, et al.
Published: (2015-06-01)

Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox
by: Liujiang Dai, et al.
Published: (2022-11-01)

Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus
by: Zuopeng Wang, et al.
Published: (2023-05-01)

The potential mechanism of Aidi injection against neuroblastoma—an investigation based on network pharmacology analysis
by: Shuyang Dai, et al.
Published: (2024-01-01)

Network pharmacology and molecular docking study on the mechanism of chronic prostatitis treatment using Xiaochaihutang
by: Jian Wang, et al.
Published: (2023-11-01)

Network pharmacology used to decode potential active ingredients in Ferula assafoetida and mechanisms for the application to Alzheimer’s disease
by: Meng Xu, et al.
Published: (2020-04-01)

Study on the Potential Mechanism of Tonifying Kidney and Removing Dampness Formula in the Treatment of Postmenopausal Dyslipidemia Based on Network Pharmacology, Molecular Docking and Experimental Evidence
by: Xuewen Li, et al.
Published: (2022-07-01)

The therapeutic effect and targets of cellulose polysaccharide on coronary heart disease (CHD) and the construction of a prognostic signature based on network pharmacology
by: Lang Liu, et al.
Published: (2022-10-01)

Network pharmacology and in vivo evidence of the pharmacological mechanism of geniposide in the treatment of atherosclerosis
by: Guiping Ma, et al.
Published: (2024-01-01)

The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance
by: Min Wang, et al.
Published: (2023-11-01)

Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data
by: Yinglian Pan, et al.
Published: (2019-08-01)

PIK3CA, KI67, Estrogen (ER) and Progesterone Receptors (PR) Expression Pattern of in HER2 Positive Breast Cancers
by: Samuel I. Ogenyi, et al.
Published: (2022-02-01)

Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal
by: Leonor Vasconcelos de Matos, et al.
Published: (2023-12-01)

Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants
by: Arman Ali Ghodsinia, et al.
Published: (2020-04-01)

Pulmonary Vein Stenosis Associated with Germline <i>PIK3CA</i> Mutation
by: Delphine Yung, et al.
Published: (2022-05-01)

Lateralized and Segmental Overgrowth in Children
by: Alessandro Mussa, et al.
Published: (2021-12-01)